Ritonavir was developed as a protease inhibitor and is now almost never used for its antiviral effect. At low dose it serves as a pharmacokinetic booster, slowing the liver's breakdown of other drugs.
How did that change come about?
By accident, in effect. Ritonavir at full antiviral dose was poorly tolerated, and researchers noticed it dramatically raised the levels of other protease inhibitors taken alongside it. That side effect turned out to be more useful than the drug itself.
How does boosting work?
The liver enzyme CYP3A4 breaks down many medicines, including several antiretrovirals, quickly enough that impractical doses would be needed. Ritonavir inhibits it potently. With the enzyme blocked, the partner drug is cleared more slowly.
Does it still have antiviral activity?
Negligible at the 100mg doses used for boosting. At the 600mg twice-daily antiviral dose it did, and that dose is no longer used because of how poorly people tolerated it.
Why did boosting matter so much?
Because before it, protease inhibitors required large doses several times a day with substantial side effects. Boosting made once-daily dosing feasible and transformed both tolerability and effectiveness for the class.
What is it used to boost?
Darunavir and atazanavir principally, and lopinavir, which is only available co-formulated with it. Several older protease inhibitors were boosted with it before falling out of use.
How does it compare with cobicistat?
Similar boosting effect. Cobicistat is generally better tolerated and can be co-formulated into more single tablets. Ritonavir is cheaper, has a longer record, and is preferred in pregnancy where cobicistat-boosted levels fall.
Does switching booster reduce interactions?
Barely. Both inhibit CYP3A4 potently, so the long list of affected medicines is essentially the same. This is a common misunderstanding and it matters, because removing the booster entirely is what actually changes the picture.
Does it do anything else?
It induces some other enzymes while inhibiting CYP3A4, which makes its overall behaviour slightly less predictable than cobicistat's. Some drug levels go up and some go down.
Is it used outside HIV?
Yes. Its boosting property has been applied to antiviral treatments for other conditions, which is why it sometimes appears in prescriptions unrelated to HIV. The interaction profile is the same wherever it is used.
Why is boosting less common now?
Because modern first-line regimens are built around unboosted integrase inhibitors that need no booster at all. That removes the interaction burden entirely, which is a substantial part of why they displaced boosted regimens.
Is it still important?
Yes, where a boosted protease inhibitor is specifically wanted: for resistance, for a very high resistance barrier, or in pregnancy. It is a supporting component rather than a treatment choice in itself.
Does it treat hepatitis B?
No. It has no activity against anything at boosting doses. Whatever cover a regimen provides comes from its other components.
How long has it been available?
Since 1996, so there is nearly three decades of experience with it. Its properties are exhaustively characterised.
Is it available generically?
Widely, which has made boosted regimens considerably cheaper than they once were.
Where does it sit against the alternatives?
Against cobicistat, slightly less comfortable and preferred in pregnancy. Against no booster at all, considerably worse, which is why unboosted regimens are first-line where they suit.